Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan 11;16(1):5.
doi: 10.1186/s12944-016-0400-7.

Promoting effect of hepatitis B virus on the expressoin of phospholipase A2 group IIA

Chengliang Zhu  1 , Hui Song  2 , Bingzheng Shen  1 , Long Wu  1 , Fang Liu  3 , Xinghui Liu  4
Affiliations

Promoting effect of hepatitis B virus on the expressoin of phospholipase A2 group IIA

Chengliang Zhu et al. Lipids Health Dis. .

Abstract

Background: Hepatitis B virus (HBV) infection causes acute and chronic liver disease, ultimately leading to the development of liver cirrhosis (LC) and hepatocellular carcinoma (HCC). Phospholipase A2 group IIA (PLA2G2A) plays important roles in the development and progression of many tumors. Thus far, there have been no reports on the association between HBV and PLA2G2A. The present study investigated the effect of HBV infection on PLA2G2A expression and its application in the diagnosis of HBV-related diseases.

Methods: Serum levels of PLA2G2A in 308 HBV-infected patients and 185 healthy controls were measured using an enzyme-linked immunosorbent assay (ELISA). The difference in serum levels of PLA2G2A was analyzed among chronic hepatitis B (CHB), LC, and HCC patients. PLA2G2A mRNA and protein expression in HepG2 and HepG2.2.15 cells carrying the integrated HBV genome were measured using reverse transcription polymerase chain reaction (RT-PCR) and western blot assays. The HBV infectious clone pHBV1.3, the control plasmid pBlue-ks and PLA2G2A gene promoter were transfected into HepG2 and HepG2.2.15 cells. After transfection, the luciferase activity was measured in the cells. PLA2G2A mRNA and protein expression levels were examined using RT-PCR and western blot assays.

Results: The serum levels of PLA2G2A were 258.3 ± 20.3ng/dl in the healthy controls and 329.0 ± 22.5ng/dl, 385.4 ± 29.3ng/dl and 459.2 ± 38.6ng/dl in the CHB, LC, and HCC patients, respectively. Statistical analyses revealed significantly higher serum levels of PLA2G2A in CHB, LC, and HCC patients than in the healthy controls (P < 0.05), and PLA2G2A levels were elevated in the order of HCC > LC > CHB group. High serum PLA2G2A levels in HCC patients were associated with a lower prevalence of lymph node metastasis and a lower TNM stage. HepG2.2.15 cells carrying the HBV genome expressed higher levels of PLA2G2A mRNA and protein than the HepG2 cells. In addition, HBV triggered PLA2G2A promoter activity and enhanced PLA2G2A mRNA and protein expression compared to the empty vector pBlue-ks.

Conclusion: HBV can upregulate the expression of PLA2G2A, and serum levels of PLA2G2A are associated with the progression of HBV-related diseases.

Keywords: Chronic hepatitis B; Hepatitis B virus; Hepatocellular carcinoma; Liver cirrhosis; Phospholipase A2 group IIA.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Serum PLA2G2A levels in healthy controls and HBV patients. The serum PLA2G2A levels in the healthy controls and in CHB, LC, and HCC patients were measured using an ELISA. *P < 0.05
Fig. 2
Fig. 2
PLA2G2A mRNA and protein expression in HepG2 and HepG2.2.15 cells. a The relative mRNA levels of PLA2G2A in the HepG2 and HepG2.2.15 cells were measured using RT-PCR analysis. b PLA2G2A protein expression in HepG2 and HepG2.2.15 cells was measured using western blotting
Fig. 3
Fig. 3
Effect of HBV on the activity of the PLA2G2A promoter. a HepG2 cells were co-transfected with pHBV1.3/pBlue-ks and the PLA2G2A promoter pPLA2G2A-Luc plasmid, and then luciferase activity was measured. b HepG2 and HepG2.2.15 cells were transfected with PLA2G2A promoter pPLA2G2A-Luc plasmid, and then luciferase activity was measured. *P < 0.05
Fig. 4
Fig. 4
Effect of pHBV1.3 on PLA2G2A mRNA and protein expression. a Effects of pHBV1.3 on the expression of PLA2G2A mRNA. HepG2 cells were transfected with pHBV1.3 or pBlue-ks, and then 48 h after transfection, PLA2G2A mRNA was measured by RT-PCR analysis. b Effects of pHBV1.3 on the expression of PLA2G2A protein. HepG2 cells were transfected with pHBV1.3 or pBlue-ks, and then 48 h after transfection, PLA2G2A protein was measured using western blotting
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol. 2015;62:956–967. doi: 10.1016/j.jhep.2015.01.002. - DOI - PubMed
    1. Yamada R, Hiramatsu N, Oze T, Morishita N, Harada N, Yakushijin T, Iio S, Doi Y, Yamada A, Kaneko A, et al. Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection. J Gastroenterol. 2015;50:785–794. doi: 10.1007/s00535-014-1010-7. - DOI - PubMed
    1. Wang X, Wang N, Cheung F, Lao L, Li C, Feng Y. Chinese medicines for prevention and treatment of human hepatocellular carcinoma: current progress on pharmacological actions and mechanisms. J Integr Med. 2015;13:142–164. doi: 10.1016/S2095-4964(15)60171-6. - DOI - PubMed
    1. Sunbul M. Hepatitis B virus genotypes: global distribution and clinical importance. World J Gastroenterol. 2014;20:5427–5434. doi: 10.3748/wjg.v20.i18.5427. - DOI - PMC - PubMed
    1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264–1273. doi: 10.1053/j.gastro.2011.12.061. - DOI - PMC - PubMed

MeSH terms